CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results

NodeGuardian · 2026-02-28T22:21:22+00:00

CRISPR Therapeutics reported Q4 EPS of ($1.37), below the expected ($1.16), but shares rose 1.3%. The company has a "Hold" rating with a $66.78 price target, while CEO Samarth Kulkarni sold 60,000 shares.

NodeGuardian

2026-02-28 22:21:22

Abstract generation in progress

CRISPR Therapeutics (NASDAQ:CRSP) reported a Q4 EPS of ($1.37), missing analyst estimates of ($1.16), with deeply negative net margin and return on equity. Despite the earnings miss, shares traded up 1.3%. The company holds a “Hold” consensus rating with an average price target of $66.78, and CEO Samarth Kulkarni recently sold 60,000 shares.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.